Pacific Edge Full Year Result to be Announced 25 May 2023

Company Announcement
1 May 2023

PACIFIC EDGE FULL YEAR RESULT TO BE ANNOUNCED 25 MAY 2023

Cancer diagnostics company Pacific Edge Limited (NZX:PEB) advises that its full year results for the 12 months to 31
March 2023 (FY23) will be released on Thursday 25 May 2023, prior to 10am.

This will be followed by an Investor and Analyst conference call at 11.00am (NZST). This investor briefing will be
available via webcast by the following link: www.virtualmeeting.co.nz/pebfy23 or by phone on the following toll
free numbers:

New Zealand: 0800 449 170
Australia: 1800 896 574

Questions
Questions can be submitted online in writing via the Webcast platform or verbally via the audio call system when
prompted.


If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley
on 03 479 5807 or stacey.stanley@pelnz.com.


ENDS


Approved for release by:

Grant Gibson
Chief Financial Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and
commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of
recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through
its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

ABOUT CXBLADDER www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder
evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection,
surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing
and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the
clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists
in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New
Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the
test online.